We also found that low FBXO11 expression in MDS (third quartile) was associated with a greater number of disease-associated alternative splicing events than was seen in samples with high FBXO11 expression (first quartile) compared with healthy controls (Figure 3I). This evidence concerns the gene FBXO11 and myelodysplastic syndrome.